How Ryeqo Works

Ryeqo is a GnRH antagonist combined with add-back therapy in a single, once-daily pill1

‍

Relugolix drives improvements in the symptoms of endometriosis and uterine fibroids, while add-back therapy minimises effects typical of hypoestrogenic states, providing a balance between efficacy and safety.1–8

Designed to delicately balance efficacy & safety:1,2

*The estrogen threshold hypothesis proposes that maintenance of the E2 concentration within a specific range (i.e. 20–50 pg/mL) can cause regression in endometriosis5 and uterine fibroids symptoms while minimising hypoestrogenic adverse events.

Abbreviations: ABT, add-back therapy; BMD, bone mineral density; E2, estradiol; GnRH, gonadotropin-releasing hormone.

‍

References:

  1. Giudice LC et al. Lancet. 2022;399:2267–2279.
  2. Ryeqo Approved Product Information. January 2024.
  3. Duijkers L et al. Oral abstract ASRM, 2020. Abstract 0–196.
  4. Barbieri RL. Am J Obstet Gynecol. 1992;166:170–175.
  5. Friedman AJ et al. Am J Obstet Gynecol. 1990;163:1114–1119.
  6. Al-Hendy A et al. N Engl J Med. 2021;384:630–642.
  7. Donnez J et al. J Clin Med. 2021;10:1085.
  8. Al-Hendy A et al. Obstet Gynecol. 2022;140(6):920–930.